Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma

Recruiting in Palo Alto (17 mi)

+5 other locations

Overseen byErin Reid

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: AIDS Malignancy Consortium

No Placebo Group

Approved in 2 Jurisdictions

Trial Summary

What is the purpose of this trial?

This research trial studies clinical factors and gene expression analysis for prognosis in tissue samples from patients with acquired immune deficiency syndrome (AIDS)-related primary effusion lymphoma. Gathering health information over time and studying samples of tissue from patients in the laboratory may help doctors learn about the prognosis of patients with AIDS-related primary effusion lymphoma.

Research Team

Erin Reid

Principal Investigator

AIDS Malignancy Consortium

Eligibility Criteria

Inclusion Criteria

Patients diagnosed with primary effusion lymphoma (HIV seropositive or negative) on or after January 1, 1998 on whom survival status at 2 years post PEL diagnosis is available

Participants may be enrolled to either or both the clinical or genomic portions of the study

HIV status, and for HIV subjects include cluster of differentiation (CD)4 count, HIV viral load closest to time of diagnosis

See 7 more

Treatment Details

Interventions

Laboratory Biomarker Analysis (Genetic Analysis)

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Chart review, RNA sequencing, microarrayExperimental Treatment2 Interventions

Laboratory Biomarker Analysis. Medical chart review is performed and patient information is collected regarding human immunodeficiency virus HIV/AIDS medical history, staging of AIDS related malignancy, and type of treatment. Previously collected tissue samples are analyzed via RNA sequencing and microarray.